BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 19837986)

  • 1. [Diagnostic value of specific anty-HLA alloantibodies before and after renal transplantation. Programs for highly sensitized recipients].
    Zielińska H; Zieliński M; Moszkowska G; Debska-Slizień A; Jankowska MM; Rutkowski B; Trzonkowski P
    Postepy Hig Med Dosw (Online); 2009 Sep; 63():435-48. PubMed ID: 19837986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reappraisal of HLA antibody analysis and crossmatching in kidney transplantation.
    Lee PC; Ozawa M
    Clin Transpl; 2007; ():219-26. PubMed ID: 18642453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and anti-HLA antibody profile of nine renal transplant recipients with failed grafts: donor-specific and non-donor-specific antibody development.
    Rebellato LM; Ozawa M; Verbanac KM; Catrou P; Haisch CE; Terasaki PI
    Clin Transpl; 2006; ():241-53. PubMed ID: 18365382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of human leukocyte antigen matching and recipients' panel reactive antibodies on two-year outcome in presensitized renal allograft recipients.
    Meng HL; Jin XB; Li XT; Wang HW; Lü JJ
    Chin Med J (Engl); 2009 Feb; 122(4):420-6. PubMed ID: 19302748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. De novo anti-HLA antibody responses after renal transplantation: detection and clinical impact.
    Seveso M; Bosio E; Ancona E; Cozzi E
    Contrib Nephrol; 2009; 162():87-98. PubMed ID: 19001816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relevance of different antibody detection methods for the prediction of antibody-mediated rejection and deceased-donor kidney allograft survival.
    Vlad G; Ho EK; Vasilescu ER; Colovai AI; Stokes MB; Markowitz GS; D'Agati VD; Cohen DJ; Ratner LE; Suciu-Foca N
    Hum Immunol; 2009 Aug; 70(8):589-94. PubMed ID: 19375470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The increasing clinical importance of alloantibodies in kidney transplantation.
    Pankewycz O; Soliman K; Laftavi MR
    Immunol Invest; 2014; 43(8):775-89. PubMed ID: 25296233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical relevance of pre and post-transplant immune markers in kidney allograft recipients: anti-HLA and MICA antibodies and serum levels of sCD30 and sMICA.
    Solgi G; Furst D; Mytilineos J; Pourmand G; Amirzargar AA
    Transpl Immunol; 2012 Mar; 26(2-3):81-7. PubMed ID: 22182633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical relevance of pre- and post-transplant HLA antibodies, donor-specific, and nondonor-specific HLA antibodies detected by ELISA in renal transplantation.
    Lee PC; Chen YL; Wang WM; Tu WC; Chen HY
    Clin Transpl; 2013; ():385-91. PubMed ID: 25095533
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of antibody-mediated kidney transplant rejection.
    Morath C; Opelz G; Zeier M; Süsal C
    Transpl Int; 2012 Jun; 25(6):633-45. PubMed ID: 22587522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Donor-specific HLA antibodies in paediatric cardiac transplant recipients are associated with poor graft survival.
    Irving C; Carter V; Parry G; Hasan A; Kirk R
    Pediatr Transplant; 2011 Mar; 15(2):193-7. PubMed ID: 21199210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidences of preformed and de novo donor-specific HLA antibodies and their clinicohistological correlates in the early course of kidney transplantation.
    Huang Y; Ramon D; Luan FL; Sung R; Samaniego M
    Clin Transpl; 2012; ():247-56. PubMed ID: 23721029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of HLA antibodies on graft survival in long-term renal recipients with functional grafts.
    Zeng Y; Liu Z; Liu Y; Fan Y; Guo Y; Qiu J
    Urol Int; 2014; 92(3):328-33. PubMed ID: 24480999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term follow up for anti-HLA donor specific antibodies postrenal transplantation: high immunogenicity of HLA class II graft molecules.
    Ntokou IS; Iniotaki AG; Kontou EN; Darema MN; Apostolaki MD; Kostakis AG; Boletis JN
    Transpl Int; 2011 Nov; 24(11):1084-93. PubMed ID: 21848902
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of HLA-specific antibodies in kidney transplant rejection: published studies and local data.
    Worthington JE; Martin S; Barker AJ; McWilliam LJ; Dyer PA
    Clin Transpl; 2006; ():349-61. PubMed ID: 18365389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection and clinical relevance of donor specific HLA antibodies: a matter of debate.
    Roelen DL; Doxiadis II; Claas FH
    Transpl Int; 2012 Jun; 25(6):604-10. PubMed ID: 22587521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibody-mediated rejection.
    Akalin E; Watschinger B
    Semin Nephrol; 2007 Jul; 27(4):393-407. PubMed ID: 17616272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Poor graft outcome in recipients with de novo donor-specific anti-HLA antibodies after living related kidney transplantation.
    Li X; Ishida H; Yamaguchi Y; Tanabe K
    Transpl Int; 2008 Dec; 21(12):1145-52. PubMed ID: 18803618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of alloantibody strength in crossmatch negative DSA positive kidney transplantation.
    Wu P; Jin J; Everly MJ; Lin C; Terasaki PI; Chen J
    Clin Biochem; 2013 Oct; 46(15):1389-93. PubMed ID: 23726814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A report of the epidemiology of de novo donor-specific anti-HLA antibodies (DSA) in "low-risk" renal transplant recipients.
    Rebellato LM; Everly MJ; Haisch CE; Ozawa M; Briley KP; Parker K; Catrou PG; Bolin P; Kendrick WT; Kendrick SA; Harland RC
    Clin Transpl; 2011; ():337-40. PubMed ID: 22755428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.